Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Common Equity (2016 - 2025)

IGC Pharma has reported Common Equity over the past 15 years, most recently at $8.1 million for Q3 2025.

  • Quarterly Common Equity rose 9.69% to $8.1 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $8.1 million through Sep 2025, up 9.69% year-over-year, with the annual reading at $6.3 million for FY2025, 13.54% down from the prior year.
  • Common Equity was $8.1 million for Q3 2025 at IGC Pharma, up from $6.1 million in the prior quarter.
  • Over five years, Common Equity peaked at $32.8 million in Q1 2021 and troughed at $6.1 million in Q2 2025.
  • The 5-year median for Common Equity is $14.1 million (2023), against an average of $16.3 million.
  • Year-over-year, Common Equity surged 37.27% in 2021 and then crashed 50.9% in 2024.
  • A 5-year view of Common Equity shows it stood at $29.5 million in 2021, then plummeted by 37.86% to $18.3 million in 2022, then tumbled by 50.58% to $9.1 million in 2023, then tumbled by 30.86% to $6.3 million in 2024, then increased by 29.29% to $8.1 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Common Equity are $8.1 million (Q3 2025), $6.1 million (Q2 2025), and $6.3 million (Q1 2025).